TARRYTOWN, N.Y., Aug. 10 /PRNewswire/ -- Bayer HealthCare, Diagnostics Division, a member of the Bayer Group , announced today the availability of its new Tnl-Ultra(TM) Troponin assay on ADVIA Centaur(R) CP Immunoassay system. The launch of the TnI-Ultra assay on ADVIA Centaur CP provides additional options for high sensitivity troponin testing on Bayer's immunoassay systems. ADVIA Centaur CP TnI-Ultra assay is an addition to ADVIA Centaur and ADVIA IMS TnI-Ultra assays released earlier this year.
The TnI-Ultra assays aid physicians in the diagnosis of myocardial infarction and in the assessment of risk in patients with acute coronary syndrome. The assays are the first fully-automated troponin assays meeting the European Society of Cardiology/American College of Cardiology recommendation of a less than or equal to 10% level of imprecision at the 99th percentile of a healthy population. Meeting the ESC/ACC criteria is a key attribute in the definition of a high sensitivity Troponin test.
"Having multiple system options for cardiovascular testing that provide concordant results is extremely important because as patients move throughout the system, the need for rebaselining or repeat testing is minimized. ADVIA Centaur CP TnI-Ultra assay is highly concordant with ADVIA Centaur and ADVIA IMS TnI-Ultra assays. This makes the laboratory's life and the physician's life easier," stated Dr. Charaf Ahnadi, clinical trial investigator for the ADVIA Centaur CP TnI-Ultra assay, Centre de Biotechnologie de Sherbrooke, Canada.
About ADVIA Centaur CP Immunoassay System
ADVIA Centaur CP, with its chemistry counterpart, ADVIA(R) 1200 Clinical Chemistry System, working with Bayer's networking and data management solution, ADVIA CentraLink(R) networking and data management solutions deliver synergies of sample handling, connectivity and system functionality to provide a complete immunoassay and clinical chemistry solution. This enables the smaller lab to offer a complete testing service without costly sample splitting and result collation.
About Bayer HealthCare Diagnostics Division
Bayer HealthCare Diagnostics Division, based in Tarrytown, New York, U.S.A, is one of the world's market leaders in diagnostics for critical and intensive care, hematology, DCA (hemoglobin A1C), urinalysis, immunology, clinical chemistry and molecular testing.
With operations in more than 100 countries, Bayer Diagnostics offers an extensive portfolio of diagnostic systems, point of care testing, molecular diagnostics, laboratory automation and productivity solutions and services to hospitals and health care organizations, laboratories and physician's offices across the world.
Bayer Diagnostics' extensive portfolio covers a myriad of disease states, including: allergy, anemia, autoimmune, cardiopulmonary care, cardiovascular/heart, congenital, diabetes, fertility, infectious diseases/AIDS, urinary tract infections, kidney, metabolic function, therapeutic drug monitoring, thyroid functions, oncology, and virology.
Bayer HealthCare Diagnostics Division operates as part of Bayer HealthCare LLC, a member of the worldwide Bayer HealthCare group.
About Bayer HealthCare AG
Bayer HealthCare, a subsidiary of Bayer AG, is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. Bayer HealthCare generated sales amounting to some 9.4 billion euros and employed 33.800 people worldwide in 2005.
The company combines the global activities of the Animal Health, Consumer Care, Diabetes Care, Diagnostics and Pharmaceuticals divisions. The new Pharmaceuticals division was established on January 1, 2006, and comprises the former Biological Products and Pharmaceutical divisions. Pharmaceuticals now has three business units: Hematology/Cardiology, Oncology and Primary Care.
Bayer HealthCare's aim is to discover and manufacture products that will improve human and animal health worldwide. The products enhance well-being and quality of life by diagnosing, preventing and treating diseases.
This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in our public reports filed with the Frankfurt Stock Exchange and with the U.S. Securities and Exchange Commission (including our Form 20-F). The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.